Azetidinyl oxadiazoles as potent mGluR5 positive allosteric modulators

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 20, 2012, Pages 6469-6474

  Packiarajan, Mathivanan ^a   Ferreira, Christine G Mazza ^a   Hong, Sang Phyo ^a   White, Andrew D ^a   Chandrasena, Gamini ^a   Pu, Xiaosui ^a   Brodbeck, Robbin M ^a   Robichaud, Albert J ^a  

^a LUNDBECK RESEARCH USA   (United States)

Author keywords

Azetidinyl N cyclohexyl carboxamides and carbamates; Azetidinyl N sulfonamides; Azetidinyl oxadiazoles; mGluR5 positive allosteric modulators; PAM to NAM switching

Indexed keywords

1,2,4 OXADIAZOLE DERIVATIVE; ALKYL GROUP; AMIDE; AZETIDINE DERIVATIVE; AZETIDINYL OXADIAZOLE DERIVATIVE; CARBAMIC ACID DERIVATIVE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME INHIBITION; NONHUMAN; PHARMACOPHORE; PHYSICAL CHEMISTRY; RAT;

ALLOSTERIC REGULATION; ANIMALS; AZETIDINES; HUMANS; OXADIAZOLES; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866738528     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.08.044     Document Type: Article

References (52)

1. D.D. Schoepp, D.E. Jane, and J.A. Monn Neuropharmacology 38 1999 1431
2. J.P. Pin, T. Galvez, and L. Prezeau Pharmacol. Ther. 98 2003 325
3. R. Anwyl Neuropharmacology 56 2009 735
4. J.L. Neisewander, D.A. Baker, R.A. Fuchs, L.T. Tran-Nguyen, A. Palmer, and J.F. Marshall J. Neurosci. 20 2000 798
5. P.J. Conn, C.W. Lindsley, and C.K. Jones Trends Pharmacol. Sci. 30 2009 25
6. H. Rosenbrock, G. Kramer, S. Hobson, E. Koros, M. Grundl, and M. Grauert Eur. J. Pharmacol. 639 2010 40
7. T. Abe, H. Sugihara, H. Nawa, R. Shigemoto, N. Mizuno, and S. Nakanishi J. Biol. Chem. 267 1992 13361
8. M.I. Bell, P.J. Richardson, and K. Lee J. Neurochem. 81 2002 142
9. G.G. Kinney, M. Burno, U.C. Campbell, L.M. Hernandez, D. Rodriguez, L.J. Bristow, and P.J. Conn J. Pharmacol. Exp. Ther. 306 2003 116
10. H. Homayoun, M.R. Stefani, B.W. Adams, G.D. Tamagan, and B. Moghaddam Neuropsychopharmacology 29 2004 1259
11. L. Lecourtier, H. Homayoun, G. Tamagnan, and B. Moghaddam Biol. Psychiatry 62 2007 739
12. J.M. Darrah, M.R. Stefani, and B. Moghaddam Behav. Pharmacol. 19 2008 225
13. L.E. Chavez-Noriega, M.J. Marino, H. Schaffhauser, U.C. Campbell, and P.J. Conn Curr. Neuropharmacol. 3 2005 9
14. G.G. Kinney, J.A. O'Brien, W. Lemaire, M. Burno, D.J. Bickel, M.K. Clements, T.B. Chen, D.D. Wisnoski, C.W. Lindsley, P.R. Tiller, S. Smith, M.A. Jacobson, C. Sur, M.E. Duggan, D.J. Pettibone, P.J. Conn, and D.L. Williams Jr. J. Pharmacol. Exp. Ther. 313 2005 199
15. F. Liu, S. Grauer, C. Kelley, R. Navarra, R. Graf, G. Zhang, P.J. Atkinson, M. Popiolek, C. Wantuch, X. Khawaja, D. Smith, M. Olsen, E. Kouranova, M. Lai, F. Pruthi, C. Pulicicchio, M. Day, A. Gilbert, M.H. Pausch, N.J. Brandon, C.E. Beyer, T.A. Comery, S. Logue, S. Rosenzweig-Lipson, and K.L. Marquis J. Pharmacol. Exp. Ther. 327 2008 827
16. M.H. Chan, P.H. Chiu, J.H. Sou, and H.H. Chen Psychopharmacology (Berl) 198 2008 141
17. G.G. Kinney, J.A. O'Brien, W. Lemaire, M. Burno, D.J. Bickel, M.K. Clements, T.B. Chen, D.D. Wisnoski, C.W. Lindsley, P.R. Tiller, S. Smith, M.A. Jacobson, C. Sur, M.E. Duggan, D.J. Pettibone, P.J. Conn, and D.L. Williams Jr. J. Pharmacol. Exp. Ther. 313 2005 199
18. C. Schlumberger, M. Pietraszek, A. Gravius, and W. Danysz Pharmacol. Biochem. Behav. 95 2010 23
19. J.T. Gass, and M.F. Olive Biol. Psychiatry 65 2009 717
20. M.F. Olive Eur. J. Pharmacol. 639 2010 47
21. J.M. Darrah, M.R. Stefani, and B. Moghaddam Behav. Pharmacol. 19 2008 225
22. J.M. Uslaner, S. Parmentier-Batteur, R.B. Flick, N.O. Surles, J.S. Lam, C.H. McNaughton, M.A. Jacobson, and P.H. Hutson Neuropharmacology 57 2009 531
23. J.E. Ayala, Y. Chen, J.L. Banko, D.J. Sheffler, R. Williams, A.N. Telk, N.L. Noreen L Watson, Z. Xiang, Y. Zhang, P.J. Jones, C.W. Lindsley, M.F. Olive, and P.J. Conn Neuropsychopharmacology 34 2009 2057
24. R.S. Stauffer ACS Chem. Neurosci. 2 2011 450
25. R.M. Cleva, and F.M. Olive Molecules 16 2011 2097
26. J.A. O'Brien, W. Lemaire, T.B. Chen, R.S. Chang, M.A. Jacobson, S.N. Ha, C.W. Lindsley, H.J. Schaffhauser, C. Sur, D.J. Pettibone, P.J. Conn, and D.L. Wiliams Mol. Pharmacol. 64 2003 731
27. C.W. Lindsley, D.D. Wisnoski, W.H. Leister, J.A. O'Brien, W. Lemiare, D.L.J. Williams, M. Burno, C. Sur, G.G. Kinney, D.J. Pettibone, P.R. Tiller, S. Smith, M.E. Duggan, G.D. Hartman, P.J. Conn, and J.R. Huff J. Med. Chem. 47 2004 5825
28. G.G. Kinney, J.A. O'Brien, W. Lemaire, M. Burno, D.J. Bickel, M.K. Clements, T.-B. Chen, D.D. Wisnoski, C.W. Lindsley, P.R. Tiller, S. Smith, M.A. Jacobson, C. Sur, M.E. Duggan, D.J. Pettibone, P.J. Conn, and D.L. Williams J. Pharmacol. Exp. Ther. 313 2005 199
29. Y. Chen, Y. Nong, C. Goudet, K. Hemstapat, T. de Paulis, J.P. Pin, and P.J. Conn Mol. Pharmacol. 71 2007 1389
30. Bessis, A.-S.; Bonnet, B.; Le Poul, E.; Rocher, J.-P.; Epping-Jordan, M. P. PCT Pat. Appl. WO 2005/044797, 2005.
31. M.P. Epping-Jordan, S. Nayak, F. Derouet, H. Dominguez, A.S. Bessis, E. Le Poul, B.L. Ludwig, V. Mutel, S.M. Poli, and J.P. Rocher Neuropharmacology 49 2005 231
32. D.W. Engers, A.L. Rodriguez, R. Williams, A.S. Hammond, D. Venable, O. Oluwatola, G.A. Sulikowski, P.J. Conn, and C.W. Lindsley Chem. Med. Chem. 4 2009 505
33. J.P. Lamb, D.W. Engers, C.M. Niswender, A.L. Rodriguez, D.F. Venable, P.J. Conn, and C.W. Lindsley Bioorg. Med. Chem. Lett. 21 2011 2711
34. M.-F. Zou, J. Cao, A.L. Rodriguez, P.J. Conn, and A.H. Newman Bioorg. Med. Chem. Lett. 21 2011 2650
35. R. Williams, J.T. Manka, A.L. Rodriguez, P.N. Vinson, C.M. Niswender, C.D. Weaver, C.D. Jones, P.J. Conn, C.W. Lindsley, and S.R. Stauffer Bioorg. Med. Chem. Lett. 21 2011 1350
36. Y. Zhou, J.T. Manka, A.L. Rodriguez, C.D. Weaver, E.L. Days, P.N. Vinson, S. Jadhav, E.J. Hermann, C.K. Jones, P.J. Conn, C.W. Lindsley, and S.R. Stauffer ACS Med. Chem. Lett. 1 2010 433
37. D.W. Engers, A.L. Rodriguez, R. Williams, A.S. Hammond, D. Venable, O. Oluwatola, G.A. Sulikowski, P.J. Conn, and C.W. Lindsley ChemMedChem 4 2009 505
38. S. Sharma, J. Kedrowski, J.M. Rook, R.L. Smith, C.K. Jones, A.L. Rodriguez, P.J. Conn, and C.W. Lindsley J. Med. Chem. 52 2009 4103
39. H. Xiong, T.A. Brugel, M. Balestra, D.G. Brown, K.A. Brush, C. Hightower, L. Hinkley, V. Hoesch, J. Kang, G.M. Koether, J.P. McCauley Jr., F.M. McLaren, L.M. Panko, T.R. Simpson, R.W. Smith, J.M. Woods, B. Brockel, V. Chhajlani, R.A. Gadient, N. Spear, L.A. Sygowski, M. Zhang, J. Arora, N. Breysse, J.M. Wilson, M. Isaac, A. Slassi, and M.M. King Bioorg. Med. Chem. Lett. 20 2010 7381
40. J.G. Varnes, A.P. Marcus, R.C. Mauger, S.C. Throner, V. Hoesch, M.M. King, X. Wang, L.A. Sygowski, N. Spear, R. Gadient, D.G. Brown, and J.B. Campbell Bioorg. Med. Chem. Lett. 21 2011 1402
41. N. Spear, R.A. Gadient, D.E. Wilkins, M. Do, J.S. Smith, K.L. Zeller, P. Schroeder, M. Zhang, J. Arora, and V. Chhajlani Eur. J. Pharm. 659 2011 146
42. A. Ritzen, J.M. Mathiesen, and C. Thomsen Basic Clin. Pharmacol. Toxicol. 97 2005 202
43. A. Ritzén, R. Sindet, M. Hentzer, N. Svendsen, R.M. Brodbeck, and C. Bundgaard Bioorg. Med. Chem. Lett. 19 2009 3275
44. A.G. Sams, G.K. Mikkelsen, R.M. Brodbeck, X. Pu, and A. Ritzén Bioorg. Med. Chem. Lett. 21 2011 3407
45. M. Packiarajan, C.G.-M. Ferreira, S-P. Hong, A.D. White, G. Chandrasena, X. Pu, R.M. Brodbeck, and A.J. Robichaud Bioorg. Med. Chem. Lett. 22 2012 5658
46. B. Brenda Pipik, G.-J. Ho, M. Williams, and D.A. Conlon Synth. Commun. 34 2004 186
47. E. Ester Muraglia, S. Altamura, D. Branca, O. Cecchetti, F. Ferrigno, M.V. Orsale, M.C. Palumbi, M. Rowley, R. Scarpelli, C. Steinkühler, and P. Jones Bioorg. Med. Chem. Lett. 18 2008 6083
48. 80 response to l-glutamate in the presence of test compound.
49. The solubility (μM) was measured from DMSO stock solution of the test compound (300 μL) diluted with 2 × 200μL, 25 mM potassium phosphate buffer in a titer plate shaker at a speed of 1.8 for 4 h. The supernatant was analyzed by waters acquity UPLC system (column: acquity UPLC BEH C-18, 1.7 μm 2.1 × 50 mm column and PDA detector at 254 nm for quantification) with a gradient (mobile phase A: 2% (w/v) ammonium formate and 20% acetonitrile in water, mobile phase B: 100% acetonitrile) for 2 min.
50. R.S. Obach, J.G. Baxter, T.E. Liston, B.M. Silber, B.C. Jones, F. Macintyre, D.J. Rance, and P. Wastall J. Pharmacol. Exp. Ther. 283 1997 46 The rat and human maximum liver blood flow corresponds to 20 mL/min and 1.5 L/min, respectively
51. P.D. Leeson, and B. Springthorpe Nat. Rev. Drug Disc. 6 2007 881
52. A single dose brain and plasma PK of compounds 13n and 17c were assessed at 10 mg/kg, po dose in two animals at 1 h. The plasma concentrations were determined using a tandem Agilent 1100 HPLC (Agilent Technologies, Palo Alto, CA) and a TSQ Quantum MS (Thermo Finnigan, San Jose, CA) with Xcalibur software and averaged values are shown. Compound limit of quantification (LOQ) in the brain homogenate and plasma was 2 and 10 ng/mL respectively.